RxDoctor Payments Data

Todd Kreitzer, DO

Dermatology · South Charleston, WVNPI 1841406766

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 39.0% of the total. Reporting peaked in 2023 at $940 and has fallen 62.7% since, to $350 in 2025. That places this record below the midpoint for dermatology clinicians in WV, where the typical reported total is $2,210.

$2,060in general payments, 2019–2025

Across 110 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$804
  • Lilly USA, LLC$224
  • Sun Pharmaceutical Industries Inc.$174
  • E.r. Squibb & Sons, L.L.C.$166
  • Regeneron Healthcare Solutions, Inc.$150
  • Novartis$133
  • plus $407 from 9 others

What the payments were for

  • Food & beverage$1,98596%
  • Education$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,060 in reported general payments places this provider in the 40th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$228,308
Medicare patients
754
Services billed
3,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab77$310,367
OtezlaApremilast39$191,817
Humira(Cf) PenAdalimumab27$187,877
TremfyaGuselkumab11$151,935
Humira PenAdalimumab11$74,927
Dupixent SyringeDupilumab19$73,257
Clobetasol Propionate140$3,663
Betamethasone Dipropionate58$2,915
Ketoconazole167$2,768
Fluorouracil44$2,569
Mupirocin335$2,485
Triamcinolone Acetonide159$2,189
Metronidazole32$2,047
Fluocinonide54$1,952
Doxycycline Hyclate85$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$45$151,93511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 39 dermatology providers in West Virginia.

Other dermatology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →